AptaBio Therapeutics Inc. (KOSDAQ:293780)
South Korea flag South Korea · Delayed Price · Currency is KRW
8,510.00
+60.00 (0.71%)
At close: Dec 5, 2025

AptaBio Therapeutics Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22
Net Income
-20,227-29,378-12,062-10,565
Depreciation & Amortization
508.71531.35539.11484.62
Loss (Gain) From Sale of Investments
-1,042583.55244.292,494
Loss (Gain) on Equity Investments
-879.7583.54.19-
Stock-Based Compensation
253.89234.34186.65123.6
Other Operating Activities
8,48012,478-2,458631.31
Change in Accounts Receivable
-85.48-893.71--
Change in Inventory
-131.35-224.87--
Change in Accounts Payable
39.351.87--
Change in Other Net Operating Assets
-2,3313,924-549.77-1.91
Operating Cash Flow
-15,377-12,160-14,095-6,833
Capital Expenditures
-291.74-240.16-1,345-1,041
Sale (Purchase) of Intangibles
---46.6-10.36
Sale (Purchase) of Real Estate
----65.94
Investment in Securities
4,87113,521-9,0065,332
Other Investing Activities
-49.94-55.6260.1527.66
Investing Cash Flow
2,76912,854-12,7371,743
Long-Term Debt Issued
--38,900-
Long-Term Debt Repaid
--134.01-127.85-87.95
Net Debt Issued (Repaid)
-650.28-134.0138,772-87.95
Issuance of Common Stock
---589.2
Other Financing Activities
-20.94-33.3-19.2-5.24
Financing Cash Flow
-671.22-167.3149,854496.01
Foreign Exchange Rate Adjustments
-10.69-1.195.0716.76
Miscellaneous Cash Flow Adjustments
-0-0-00
Net Cash Flow
-13,290525.3323,027-4,577
Free Cash Flow
-15,669-12,400-15,440-7,874
Free Cash Flow Margin
-455.40%-368.94%-4767.39%-16284.04%
Free Cash Flow Per Share
-622.58-526.67-692.42-353.27
Cash Interest Paid
8.6110.211.474.49
Cash Income Tax Paid
-76.1848.45-34.01
Levered Free Cash Flow
-17,255-1,924-13,398-
Unlevered Free Cash Flow
-15,931201.3-12,659-
Change in Working Capital
-2,5082,807-549.77-1.91
Source: S&P Capital IQ. Standard template. Financial Sources.